NCT00788684 2025-02-20
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Phase 1 Completed
Clinical Trials
11 trialsNCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT00481091 2023-06-13
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1/2 Completed
NCT03181126 2021-10-14
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
Phase 1 Completed
NCT00406809 2021-08-02
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Phase 1/2 Completed
NCT01121133 2017-11-21
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
AbbVie
Phase 1 Completed
NCT01087151 2016-11-02
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT01423539 2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2 Withdrawn
NCT00868413 2013-06-07
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1 Completed
NCT01021358 2010-12-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
Phase 1 Completed
NCT00743028 2010-10-07
Assess the Oral Bioavailability of New ABT-263 Formulations
Abbott
Phase 1 Completed